| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | -7,780 | 39,190 | 5,030 | 3,130 | 2,870 |
| Sales Growth | -119.85% | +679.13% | +60.70% | +9.06% | +0.70% |
| Net Income | -73,730 | -42,970 | -60,100 | -55,610 | -38,370 |
| Net Income Growth | -71.58% | +28.50% | -8.07% | -44.93% | +32.71% |
Nanobiotix S.A. ADR (NBTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NANOBIOTIX is a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases. NANOBIOTIX is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31